BridgeBio Pharma (BBIO) Earnings Date & Reports

Key Takeaways

• Revenue beat: BridgeBio reported Q1 2026 total revenue of $194.5 million, up 66.8% year-over-year, exceeding analyst consensus of approximately $178 million.
• EPS miss: The company posted a net loss of $0.84 per share, wider than the consensus estimate of -$0.70, driven by higher operating expenses related to commercialization and pipeline investments.
• Attruby dominance: Attruby (acoramidis), BridgeBio's flagship therapy for transthyretin amyloidosis cardiomyopathy (ATTR-CM), generated $180.6 million in net U.S. product revenue, a 392% increase from the prior-year quarter.
• Strengthened balance sheet: Cash, cash equivalents, and marketable securities totaled $940.2 million, up 60% from $587.5 million at the end of 2025, providing a strong runway for ongoing commercial and pipeline investments.
• Pipeline progress: BridgeBio highlighted advancement across multiple late-stage programs, including plans for a New Drug Application (NDA) submission for infigratinib in achondroplasia in the third quarter of 2026.

Earnings Context and Why It Matters

BridgeBio Pharma's Q1 2026 results marked the second full quarter of Attruby commercialization following its U.S. Food and Drug Administration (FDA) approval in November 2024. For a company transitioning from clinical-stage to commercial-stage, this report offered a critical read on two fronts: the durability of Attruby's launch trajectory in the competitive ATTR-CM market, and the pace at which operating expenses are scaling to support multiple pre-commercial pipeline programs. With Attruby competing against established therapies, every quarter of commercial data shapes investor confidence in BridgeBio's long-term revenue potential. The quarter also mattered because it preceded several anticipated pipeline catalysts expected later in 2026, making the company's financial health a key factor in its ability to execute across its diversified portfolio.

Reported Results

BridgeBio Pharma reported total net revenues of $194.5 million for the first quarter ended March 31, 2026, compared to $116.6 million in the same period a year ago. The revenue figure exceeded the consensus analyst estimate of approximately $178 million. The top-line growth was overwhelmingly driven by Attruby, which recorded $180.6 million in U.S. net product revenue—a 392% surge from $36.7 million in Q1 2025. Royalty revenue contributed $9.5 million, primarily from sales of BEYONTTRA in the European Union and Japan, while license and services revenue declined to $4.4 million due to the prior-year period benefiting from a $75 million milestone payment.

On the bottom line, BridgeBio posted a net loss attributable to common stockholders of $164.0 million, or $0.84 per share, compared to a net loss of $167.4 million, or $0.88 per share, in Q1 2025. The EPS result missed the consensus estimate of -$0.70 by $0.14. Total operating costs and expenses rose to $300.5 million from $221.0 million a year earlier, reflecting a $57.5 million increase in selling, general and administrative (SG&A) expenses tied to Attruby's commercialization and pre-launch activities for late-stage pipeline candidates. Research and development (R&D) expenses also climbed to $126.6 million from $111.4 million, supporting the advancement of key programs including infigratinib, encaleret, and BBP-418.

AI Screener

For investors seeking to identify opportunities across the biotechnology sector and beyond, Tickeron's AI Screener offers a powerful AI-driven stock and ETF discovery tool designed to streamline market analysis. The platform allows users to scan thousands of equities using customizable filters spanning technical patterns, fundamental metrics, volatility profiles, trend signals, and proprietary AI-generated ratings. Whether tracking biotech breakout candidates, monitoring earnings season movers, or screening by industry and market capitalization, the AI Screener helps traders and investors surface relevant ideas more efficiently than conventional manual screening. Explore the AI Screener to see how data-driven filtering can enhance your market research process.

Market Reaction and Investor Sentiment

BridgeBio shares initially saw a modest 1.2% uptick in after-hours trading following the May 7 earnings release, as the revenue beat and Attruby's robust growth trajectory appeared to outweigh concerns about the EPS miss. However, the stock subsequently declined approximately 2.3% over the following week, reflecting mixed investor interpretation. The revenue beat validated the commercial thesis around Attruby, but the wider-than-expected loss underscored the cost burden of scaling a multi-product commercial organization while simultaneously funding an expansive pipeline. Since then, BBIO shares have rallied significantly, reaching a 52-week high of $93.42 on July 9, 2026, partially supported by positive sentiment around pipeline catalysts and competitor developments in the ATTR-CM space. The stock was trading near $84 as of late July 2026, roughly 23% above its post-earnings level, indicating that investor sentiment has shifted favorably in anticipation of upcoming milestones.

Forward Outlook and Key Factors to Monitor

Looking ahead, several factors will shape BridgeBio's trajectory through the remainder of 2026. The upcoming Q2 2026 earnings report, estimated for early August, is expected to show continued revenue growth, with consensus estimates pointing to approximately $224 million in revenue and a narrower loss per share of around -$0.58. Investors will closely watch Attruby's prescription trends and any signs of plateauing or accelerating demand.

Beyond the quarterly numbers, pipeline execution remains the dominant narrative. BridgeBio has indicated plans to submit an NDA for infigratinib in achondroplasia during the third quarter of 2026, representing a potentially transformative catalyst for the company's rare disease franchise. Additionally, Phase 3 data for encaleret in autosomal dominant hypocalcemia type 1 (ADH1) is expected imminently, and the company is preparing for the potential commercial launch of BBP-418 for limb-girdle muscular dystrophy type 2I (LGMD2I/R9).

Cost discipline will also be under scrutiny. With operating expenses running above $300 million per quarter and multiple pre-commercial programs requiring investment, the pace at which BridgeBio can narrow its operating loss will influence sentiment. The company's $940 million cash position provides a cushion, but capital allocation decisions—including a previously announced $500 million share buyback program—will be closely monitored. Finally, competitive dynamics in the ATTR-CM market, including any shifts following AstraZeneca's discontinuation of Wainua, could further define BridgeBio's commercial opportunity.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations